标题
Emerging Therapies in the Management of Advanced-Stage Gastric Cancer
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-09-13
DOI
10.3389/fphar.2018.00404
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
- (2018) Benjamin J. Wolf et al. Frontiers in Immunology
- Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer.
- (2017) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.
- (2017) Ronan Joseph Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.
- (2017) Yoon-Koo Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- New development in CAR-T cell therapy
- (2017) Zhenguang Wang et al. Journal of Hematology & Oncology
- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two
- (2017) Journal for ImmunoTherapy of Cancer
- 636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY
- (2017) T. Trarbach et al. ANNALS OF ONCOLOGY
- P-282JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer
- (2016) Van Cutsem Eric et al. ANNALS OF ONCOLOGY
- Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
- (2016) M. Schuler et al. ANNALS OF ONCOLOGY
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Helicobacter pylori upregulates Nanog and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer
- (2016) Xin Yong et al. CANCER LETTERS
- Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells
- (2016) Ana Maria Gonzalez et al. CANCER RESEARCH
- Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
- (2016) Emiliano Calvo et al. CANCER RESEARCH
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer
- (2016) Yayi He et al. CANCER SCIENCE
- Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma
- (2016) Phu Hung Nguyen et al. CLINICAL CANCER RESEARCH
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy
- (2016) Riccardo Giampieri et al. Gastric Cancer
- Japanese gastric cancer treatment guidelines 2014 (ver. 4)
- (2016) Gastric Cancer
- Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
- (2016) Elizabeth D Thompson et al. GUT
- HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
- (2016) F. Pietrantonio et al. INTERNATIONAL JOURNAL OF CANCER
- Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.
- (2016) Tomohiro Nishina et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
- (2016) Christine Böger et al. Oncotarget
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
- (2016) Sarah Derks et al. Oncotarget
- Novel targets in the treatment of advanced gastric cancer: a perspective review
- (2016) Elisa Fontana et al. Therapeutic Advances in Medical Oncology
- CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
- (2016) Qi Zhang et al. OncoImmunology
- Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
- (2015) Ramesh K. Ramanathan et al. CANCER
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection
- (2015) Shohei Eto et al. Gastric Cancer
- Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- (2015) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric cancer stem cells: evidence, potential markers, and clinical implications
- (2015) Daniel Brungs et al. JOURNAL OF GASTROENTEROLOGY
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients
- (2015) Kai Deng et al. PLoS One
- Suppression of cancer relapse and metastasis by inhibiting cancer stemness
- (2015) Youzhi Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tight junction disruption:Helicobacter pyloriand dysregulation of the gastric mucosal barrier
- (2015) Tyler J Caron WORLD JOURNAL OF GASTROENTEROLOGY
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
- (2015) Q. J. Wang et al. Cancer Immunology Research
- Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
- (2015) S. Derks et al. Cancer Immunology Research
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date
- (2015) E. Jokinen et al. Therapeutic Advances in Medical Oncology
- Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
- (2015) Hans A. Schlößer et al. OncoImmunology
- Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
- (2015) Ronan J Kelly et al. Journal for ImmunoTherapy of Cancer
- Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer
- (2015) Derek C. Marshall et al. PLoS One
- CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells
- (2014) W. M. Lau et al. CANCER RESEARCH
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
- (2014) Suling J Lin et al. GUT
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Characteristics of gastric cancer in Asia
- (2014) Rubayat Rahman WORLD JOURNAL OF GASTROENTEROLOGY
- Expression levels of matrix metalloproteinase-9 in human gastric carcinoma
- (2014) SU-ZUAN CHEN et al. Oncology Letters
- The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
- (2014) Tasuku Matsuoka et al. Cancers
- Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression
- (2014) Antonietta Farina et al. Cancers
- Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
- (2013) Markus Chmielewski et al. IMMUNOLOGICAL REVIEWS
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Role of STAT3 in Cancer Metastasis and Translational Advances
- (2013) Mohammad Zahid Kamran et al. Biomed Research International
- Cancer stem cells: therapeutic implications and perspectives in cancer therapy
- (2013) Lu Han et al. Acta Pharmaceutica Sinica B
- Matrix Metalloproteinase-9 as a Prognostic Factor in Gastric Cancer: A Meta-Analysis
- (2012) Qiong-Wen Zhang et al. Asian Pacific Journal of Cancer Prevention
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Targeting of Hyaluronan in the Tumor Stroma
- (2012) Anne Kultti et al. Cancers
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Mechanical compression drives cancer cells toward invasive phenotype
- (2011) J. M. Tse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Indoleamine 2,3-Dioxygenase
- (2010) Hatem Soliman et al. CANCER JOURNAL
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
- (2010) C. B. Thompson et al. MOLECULAR CANCER THERAPEUTICS
- Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer
- (2009) Bharat B. Aggarwal et al. Annals of the New York Academy of Sciences
- Gastric cancer
- (2009) Vincenzo Catalano et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?
- (2008) J. M. Adams et al. CANCER RESEARCH
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More